CLSN

Celsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update

[PR Newswire] – LAWRENCEVILLE, N.J., May 8, 2014 /PRNewswire/ — Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2014 and … moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboardSee who Celsion is hiring next, click here to view […]

Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer

[PR Newswire] – LAWRENCEVILLE, N.J., Feb. 27, 2014 /PRNewswire/ — Celsion Corporation (CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboardSee who Celsion is hiring next, […]

Celsion’s OPTIMA Study: What You Need To Know

moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboardSee who Celsion is hiring next, click here to view […]

Celsion Announces FDA Clearance of the OPTIMA Study – A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer

[PR Newswire] – LAWRENCEVILLE, N.J., Feb. 24, 2014 /PRNewswire/ — Celsion Corporation (CLSN) announced today that the U.S. Food and Drug Administration (FDA) has reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-co moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboardSee who Celsion is hiring next, click here to […]

Celsion’s Newest Cancer Treatment Adds To Upside

moreView todays social media effects on CLSNView the latest stocks trending across Twitter. Click to view dashboardSee who Celsion is hiring next, click here to view […]